Anaptysbio Inc Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Anaptysbio Inc has an operating margin of -125.9%, meaning the company retains $-126 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -958.3% the prior year.
Anaptysbio Inc's revenue surged 432.0% year-over-year to $91.3M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Anaptysbio Inc has elevated debt relative to equity (D/E of 5.83), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.
With a current ratio of 9.51, Anaptysbio Inc holds $9.51 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Anaptysbio Inc generated -$135.3M in operating cash flow, capex of $358K consumed most of it, leaving -$135.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Anaptysbio Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Anaptysbio Inc generates $0.93 in operating cash flow (-$135.3M OCF vs -$145.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Anaptysbio Inc (ANAB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Anaptysbio Inc generated $91.3M in revenue in fiscal year 2024. This represents an increase of 432.0% from the prior year.
Anaptysbio Inc's EBITDA was -$114.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 30.2% from the prior year.
Anaptysbio Inc generated -$135.7M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 11.6% from the prior year.
Anaptysbio Inc reported -$145.2M in net income in fiscal year 2024. This represents an increase of 11.2% from the prior year.
Anaptysbio Inc earned $-5.12 per diluted share (EPS) in fiscal year 2024. This represents an increase of 15.8% from the prior year.
Anaptysbio Inc held $123.1M in cash against $0 in long-term debt as of fiscal year 2024.
Anaptysbio Inc had 30M shares outstanding in fiscal year 2024. This represents an increase of 14.6% from the prior year.
Anaptysbio Inc's operating margin was -125.9% in fiscal year 2024, reflecting core business profitability. This is up 832.3 percentage points from the prior year.
Anaptysbio Inc's net profit margin was -159.1% in fiscal year 2024, showing the share of revenue converted to profit. This is up 794.6 percentage points from the prior year.
Anaptysbio Inc invested $163.8M in research and development in fiscal year 2024. This represents an increase of 23.9% from the prior year.
Anaptysbio Inc spent $456K on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 99.1% from the prior year.
Anaptysbio Inc invested $358K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 55.6% from the prior year.
ANAB Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $76.3M+242.8% | $22.3M-19.8% | $27.8M-35.6% | $43.1M+293.0% | $11.0M+52.8% | $7.2M-20.3% | $9.0M+171.4% | $3.3M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $31.4M-17.0% | $37.8M-8.1% | $41.2M-3.3% | $42.6M+1.4% | $42.0M+13.4% | $37.0M+10.5% | $33.5M+8.6% | $30.9M |
| SG&A Expenses | $10.2M-3.8% | $10.6M-24.9% | $14.1M+38.6% | $10.2M+9.7% | $9.3M-24.7% | $12.3M+20.1% | $10.3M+1.0% | $10.2M |
| Operating Income | $34.7M+232.6% | -$26.2M+5.0% | -$27.5M-184.8% | -$9.7M+76.0% | -$40.3M+4.5% | -$42.2M-0.2% | -$42.1M-11.7% | -$37.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0-100.0% | $39K-11.4% | $44K+833.3% | -$6K-166.7% | $9K | $0 | N/A | $0 |
| Net Income | $15.1M+139.1% | -$38.6M+1.8% | -$39.3M-80.5% | -$21.8M+53.3% | -$46.7M-6.2% | -$43.9M-4.1% | -$42.2M-13.1% | -$37.3M |
| EPS (Diluted) | $0.52+138.8% | $-1.34-4.7% | $-1.28-103.2% | $-0.63+63.2% | $-1.71-4.3% | $-1.64-3.1% | $-1.59-12.8% | $-1.41 |
ANAB Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $353.1M+5.3% | $335.3M-20.6% | $422.1M-12.8% | $483.8M+13.2% | $427.4M+5.3% | $405.8M-10.3% | $452.4M-7.2% | $487.3M |
| Current Assets | $330.6M+13.3% | $291.9M-19.6% | $363.1M-15.9% | $431.9M+17.6% | $367.4M-1.4% | $372.4M-8.5% | $406.8M-4.9% | $428.0M |
| Cash & Equivalents | $109.8M+147.9% | $44.3M-55.1% | $98.6M-19.9% | $123.1M+71.4% | $71.8M+33.8% | $53.7M+49.3% | $36.0M+36.8% | $26.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $382.5M+0.7% | $380.0M-2.1% | $388.0M-6.0% | $413.0M-1.1% | $417.5M+16.6% | $358.1M-1.7% | $364.3M-0.7% | $366.9M |
| Current Liabilities | $38.1M+7.3% | $35.5M-19.3% | $44.0M-3.1% | $45.4M+12.4% | $40.4M+25.1% | $32.3M-13.7% | $37.4M-4.4% | $39.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$29.4M+34.2% | -$44.7M-231.5% | $34.0M-52.0% | $70.9M+617.4% | $9.9M-79.3% | $47.8M-45.8% | $88.1M-26.8% | $120.4M |
| Retained Earnings | -$822.2M+1.8% | -$837.3M-4.8% | -$798.7M-5.2% | -$759.3M-7.8% | -$704.7M-7.1% | -$658.0M-7.2% | -$614.1M-7.4% | -$571.9M |
ANAB Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$27.4M+32.0% | -$40.2M-276.1% | -$10.7M+84.0% | -$66.7M-212.7% | -$21.3M+42.8% | -$37.3M-8.5% | -$34.3M+5.8% | -$36.5M |
| Capital Expenditures | $12K-69.2% | $39K+11.4% | $35K-86.7% | $263K+697.0% | $33K+22.2% | $27K-90.4% | $280K+72.8% | $162K |
| Free Cash Flow | -$27.4M+32.1% | -$40.3M-275.2% | -$10.7M+84.0% | -$66.9M-213.4% | -$21.4M+42.7% | -$37.3M-7.7% | -$34.6M+5.5% | -$36.6M |
| Investing Cash Flow | $103.3M+183.7% | $36.4M+145.2% | $14.8M+150.5% | -$29.4M-1103.8% | -$2.4M-103.6% | $68.6M+39.5% | $49.2M+60.5% | $30.6M |
| Financing Cash Flow | -$10.4M+79.4% | -$50.5M-76.6% | -$28.6M-203.7% | $27.6M-34.2% | $41.9M+407.3% | -$13.6M-164.3% | -$5.2M-67.9% | -$3.1M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $9.7M-81.0% | $51.1M+1055.0% | $4.4M+870.2% | $456K | $0 | $0 | $0 | $0 |
ANAB Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | 45.5%+163.0pp | -117.5%-18.4pp | -99.2%-76.7pp | -22.4%+345.1pp | -367.5%+220.3pp | -587.8%-119.9pp | -467.9%+669.3pp | -1137.2% |
| Net Margin | 19.8%+193.3pp | -173.5%-31.9pp | -141.6%-91.1pp | -50.5%+374.8pp | -425.3%+186.7pp | -612.0%-143.3pp | -468.8%+655.7pp | -1124.4% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 4.3%+15.8pp | -11.5%-2.2pp | -9.3%-4.8pp | -4.5%+6.4pp | -10.9%-0.1pp | -10.8%-1.5pp | -9.3%-1.7pp | -7.7% |
| Current Ratio | 8.68+0.5 | 8.22-0.0 | 8.25-1.3 | 9.51+0.4 | 9.09-2.4 | 11.53+0.7 | 10.87-0.1 | 10.92 |
| Debt-to-Equity | -13.00-4.5 | -8.49-19.9 | 11.41+5.6 | 5.83-36.4 | 42.26+34.8 | 7.49+3.4 | 4.13+1.1 | 3.05 |
| FCF Margin | -35.9%+145.1pp | -180.9%-142.3pp | -38.7%+116.6pp | -155.3%+39.4pp | -194.6%+324.6pp | -519.3%-134.7pp | -384.6%+719.6pp | -1104.2% |
Similar Companies
Frequently Asked Questions
What is Anaptysbio Inc's annual revenue?
Anaptysbio Inc (ANAB) reported $91.3M in total revenue for fiscal year 2024. This represents a 432.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Anaptysbio Inc's revenue growing?
Anaptysbio Inc (ANAB) revenue grew by 432% year-over-year, from $17.2M to $91.3M in fiscal year 2024.
Is Anaptysbio Inc profitable?
No, Anaptysbio Inc (ANAB) reported a net income of -$145.2M in fiscal year 2024, with a net profit margin of -159.1%.
What is Anaptysbio Inc's earnings per share (EPS)?
Anaptysbio Inc (ANAB) reported diluted earnings per share of $-5.12 for fiscal year 2024. This represents a 15.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Anaptysbio Inc's EBITDA?
Anaptysbio Inc (ANAB) had EBITDA of -$114.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Anaptysbio Inc's operating margin?
Anaptysbio Inc (ANAB) had an operating margin of -125.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Anaptysbio Inc's net profit margin?
Anaptysbio Inc (ANAB) had a net profit margin of -159.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Anaptysbio Inc's free cash flow?
Anaptysbio Inc (ANAB) generated -$135.7M in free cash flow during fiscal year 2024. This represents a -11.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Anaptysbio Inc's operating cash flow?
Anaptysbio Inc (ANAB) generated -$135.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Anaptysbio Inc's total assets?
Anaptysbio Inc (ANAB) had $483.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Anaptysbio Inc's capital expenditures?
Anaptysbio Inc (ANAB) invested $358K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Anaptysbio Inc spend on research and development?
Anaptysbio Inc (ANAB) invested $163.8M in research and development during fiscal year 2024.
Does Anaptysbio Inc buy back shares?
Yes, Anaptysbio Inc (ANAB) spent $456K on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
How many shares does Anaptysbio Inc have outstanding?
Anaptysbio Inc (ANAB) had 30M shares outstanding as of fiscal year 2024.
What is Anaptysbio Inc's current ratio?
Anaptysbio Inc (ANAB) had a current ratio of 9.51 as of fiscal year 2024, which is generally considered healthy.
What is Anaptysbio Inc's debt-to-equity ratio?
Anaptysbio Inc (ANAB) had a debt-to-equity ratio of 5.83 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Anaptysbio Inc's return on assets (ROA)?
Anaptysbio Inc (ANAB) had a return on assets of -30.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Anaptysbio Inc's cash runway?
Based on fiscal year 2024 data, Anaptysbio Inc (ANAB) had $123.1M in cash against an annual operating cash burn of $135.3M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Anaptysbio Inc's Piotroski F-Score?
Anaptysbio Inc (ANAB) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Anaptysbio Inc's earnings high quality?
Anaptysbio Inc (ANAB) has an earnings quality ratio of 0.93x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Anaptysbio Inc?
Anaptysbio Inc (ANAB) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.